Suicidal Ideation (Research Overview) and ketamine research

Overview

Suicidal ideation is a clinical emergency in many contexts. Conventional antidepressants generally take weeks to act, which has motivated research into faster-acting options for acutely at-risk patients.

Conventional treatment

Standard care includes immediate safety assessment, crisis intervention, hospitalization when indicated, evidence-based psychotherapies such as DBT or CAMS, and pharmacotherapy. Lithium and clozapine carry the strongest evidence for reducing suicide risk in specific populations.

Where ketamine fits

Research has examined whether subanesthetic ketamine and intranasal esketamine can produce rapid, short-term reductions in suicidal ideation in supervised settings. Esketamine carries regulatory indications in some countries for depressive symptoms with acute suicidal ideation as an adjunct to standard care.

What current evidence suggests

Meta-analyses suggest ketamine can reduce suicidal ideation within hours, with effects often lasting days. These are bridging effects rather than stand-alone treatments and are studied alongside hospitalization and ongoing psychiatric care.